Ray Dirks Research gives placental stem cell treatments developer Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT: PLTR) a strong recommendation for the short, intermediate and long term, citing the company's performance on multiple fronts in an industry that is emerging into a sort of ‘mass market’ for healthcare.
Ray Dirks adds that Pluristem's modest market cap has a lot of room for growth, representing an enormous buying opportunity. "Pluristem is also a bargain with an approximate market cap of $100 million," he says.
Dirks says, Pluristem "is the only company that has the technology, patent position, and expertise to become the manufacturing leader. Aside from its manufacturing capabilities, Pluristem also has a growing roster of its own proprietary therapies in Phase I and II clinical trials."
He adds, "The combination of intellectual property in both manufacturing and it in its own therapeutics, position Pluristem as the market leader than can cut deals with other biotechs developing therapies in the stem cell space."
Dirks cites Pluristem's announcement of the expansion of its Israeli manufacturing plant, which will produce cells for the treatment of over 150,000 patients annually when it commences operations in late 2012. The company’s proprietary 3D manufacturing process can mass produce cells in a way that no other stem cell company can, making Pluristem the ideal manufacturing partner for other stem cell companies.
Pluristem fell 1.3% on Nasdaq yesterday to $2.45, giving a market cap of $105 million, but rose 3% by midday on the TASE today to NIS 9.22.
Published by Globes [online], Israel business news - www.globes-online.com - on October 18, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011